Compare MasterCard Inc (MA) vs Moderna, Inc. (MRNA) Price & Performance

Mastercard (MA) trades at $574.76, up 0.82% with strong bullish technical signals. The company demonstrates robust fundamentals with 2025 revenue of $32.79B and net income of $14.97B, maintaining exceptional profit margins above 45%. Recent earnings consistently beat expectations, with Q2 2026 EPS of $5.04 surpassing the $4.77 estimate. Analyst consensus remains overwhelmingly positive with 80% buy ratings and a $666.67 price target.

Mastercard presents a compelling growth opportunity with expanding digital payment adoption and strong financial performance. Key risks include payment industry disruption from stablecoins and AI-driven alternatives, though the company's aggressive innovation strategy positions it well. The stock trades at premium valuations (P/E 31.6) but justifies this with consistent earnings growth and market leadership.

Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.

The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.